In this era of financial strain, popular expectations are that venture capitalists are primarily funding later- rather than early-stage companies. Data indicate, however, that venture capital funding of early-stage companies, although more selective, is still available for the strongest candidate and management packages. Likewise, major pharmaceutical companies, although right-sizing their own operations, desire to in-source compounds from small and midsize companies. For all players, therefore, time means money. Product profile and quality in a highly competitive market are paramount! TigerTox, a pharmaceutical toxicology consulting firm, ensures that the money and time allocated to drug development is strategically spent on the best toxicological package to support all stages of the proposed clinical development plan. We do it Right the First Time by ensuring that all studies are performed correctly and expediently, with the right documentation and oversight, and in a cost effective manner!  Inquiries are welcomed by phone (760-943-0447, Pacific Standard Time) or via our contact form. Complete confidentiality is assured!